Viruses, human biological materials and quality solutions for research
and technological development.
Fiocruz's Biodiversity and Health Biobank (BBS-Fiocruz) constitutes an important service platform for research, technological development, and innovation in the health field.
BBS-Fiocruz, initially called Fiocruz's COVID-19 Biobank, was created as part of the initiatives to combat the COVID-19 pandemic and was launched in December 2021. Funded by the Ministry of Health, the initiative aimed to provide an appropriate infrastructure for the safe, reliable, ethical, legal, and traceable storage of human biological material and biodiversity (viruses) related to COVID-19. In 2023, with the end of the Public Health Emergency of International Concern and the need to store Human Biological Material related to other public health problems and other viruses of taxonomic, epidemiological, and biotechnological interest, Fiocruz's Deliberative Council (DC) approved the expansion of the scope of action and changed the name of the Fiocruz COVID- 19 Biobank to the Fiocruz
The Presidency of Fiocruz inaugurates this Monday (12/13) the COVID-19 Biobank (BC19-Fiocruz), a pioneering initiative that gathers human and non-human materials in a single infrastructure. BC19-Fiocruz is one of the Foundation's actions to face the Covid-19 pandemic and constitutes a legacy for research, technological development, and innovation in health care.
BBS-Fiocruz constitutes biotechnological infrastructure and serves as a center that provides services and biological materials, facilitating collaborative initiatives at a national and international level.
The services offered by BBS-Fiocruz are related to its collections: the Human Biological Material Collection, the Virus Collection, and the Environmental Collection.
The scope of this collection includes the isolation, deposit, identification, authentication, preservation, and supply services for viruses of taxonomic, epidemiological, and biotechnological interest.
Within the scope of this collection, Human Biological Material related to COVID-19 and other diseases of public health interest are provided for research and technological development purposes.
The scope of this collection includes the deposit and supply of environmental samples from the FioAntar Project.
| Por: Elisandra Galvão | VPPCB/Fiocruz
Discussion took place (3/23) in the session 'Building capacity to ensure benefit sharing from the global DSI system', organized by the DSI Scientific Network.
| Por: VPPCB/Fiocruz
Information about BC19-Fiocruz was released in the April newsletter of the Global Genome Biodiversity Network (GGBN).
| Por: Elisandra Galvão | VPPCB/Fiocruz
A committee formed by representatives of the Japan International Cooperation Agency (JICA) and the National Institute of Infectious Diseases (NIID), both based in Tokyo (Japan), visited Fiocruz Covid-19 Biobank (BC19-Fiocruz) this week.